Stéphane Bancel defended his melanoma data and argued that rivals can’t easily copy the technology.

Investors had “incredibly high” expectations around the Phase 3 data for the drugmaker’s experimental cancer treatment.

Moderna released full data on its closely watched cancer vaccine developed with Merck.

The drop is a sharp reversal of a massive 2026 stock rally fueled by optimism over its personalized cancer vaccine.

The first Phase 3 data for a custom cancer vaccine has raised questions about whether the potential new treatment is needed.

Moderna (NasdaqGS:MRNA) and Merck reported detailed Phase 3 data for their individualized mRNA melanoma vaccine plus KEYTRUDA ...

Moderna Inc. Chief Executive Officer Stephane Bancel said he believes the personalized mRNA cancer vaccine his company is ...

The company’s stock dropped after details of a study raised questions about how widely the treatment would be used.

Personalized mRNA vaccines against melanoma—the deadliest form of skin cancer—reduced the risk of death or recurrence by 42 ...

Moderna shares are taking a hit after the leak of highly anticipated details about the company’s vaccine for the skin cancer ...

Severe sunburn increases the risk of developing melanoma, the most serious type of skin cancer. Credit: Olga Pankova/Getty. A ...

The results, which triggered Moderna’s stock to drop, are “really encouraging,” says Karen Knudsen, CEO of the Parker ...